08:00 , Dec 5, 2005 |  BC Week In Review  |  Clinical News

Holly Graft System update

CABG suspended enrollment in an international trial after 2 of 8 grafts occluded prior to the patients' discharge from the hospital. Patients were treated with an anticoagulant regimen of aspirin and warfarin. Previously, the first...
07:00 , May 9, 2005 |  BC Week In Review  |  Clinical News

Holly Graft System update

CABG Medical Inc. (CABG), Minneapolis, Minn.   Product: Holly Graft System   Business: Cardiovascular   Molecular target: Not applicable   Description: Paclitaxel-eluting graft system   Indication: Facilitate coronary artery bypass graft (CABG) surgery   Endpoint:...
08:00 , Mar 28, 2005 |  BC Week In Review  |  Company News

Angiotech, CABG deal

ANP granted CABG an exclusive license to use paclitaxel drug-eluting technology in CABG's Holly Graft System. The Holly Graft System is a polytetrafluoroethylene (ePTFE) graft that can be attached to the coronary arteries to avoid...
03:24 , Mar 24, 2005 |  BC Extra  |  Company News

Angiotech paclitaxel-eluting graft deal

Angiotech (TSX:ANP; ANPI) granted CABG Medical ( CABG ) an exclusive license to use paclitaxel drug-eluting technology in CABG's Holly Graft System. The Holly Graft System is a polytetrafluoroethylene (ePTFE) graft that can be attached...